Kt&g Life Sciences Corp.

Genetic therapies compete in the same indications, as degraders come of age

BioCentury’s roundup of translational innovation also includes a new target for arrhythmia and four papers with links to newcos

Deal for up to $1.1B with ‘significant upfront payment’ rewards syndicate including Westlake and Versant, gives pharma three preclinical programs for muscular dystrophies

At ASGCT meeting, Westlake and Versant-backed Kate Therapeutics shows its AAV gene therapy targets muscle, heart in primates

Targets, mechanisms and indications that stand to benefit from the surging interest in dermatology

Japanese pharma has done a dozen therapeutics deals so far this year, with at least seven showcasing how it’s building within defined focus areas

BioCentury’s roundup of translational innovations

Plus: Axsome taps investors for $225M, and updates from Immutep, K36, Pfizer, Zai Lab and more

Kate’s platform for increasing the potency and decreasing the liver tox of AAVs has attracted Astellas as a partner

Plus: two Sangamo partnerships end, Gilead adds Nurix’s degrader